AC Immune SA (ACIU) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 20-F, AC Immune SA's filing signal continuing negative.

AC Immune SA is a clinical-stage biopharmaceutical company focused on developing precision medicine for neurodegenerative diseases, leveraging its proprietary SupraAntigen and Morphomer technology platforms. The company's strategy targets multiple protein pathologies implicated in Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative disorders, utilizing both active immunotherapies and small molecule drug candidates. AC Immune has established significant partnerships with major pharmaceutical companies like Janssen, Eli Lilly, and Takeda, which contribute to its development pipeline and provide non-dilutive capital. The company's pipeline includes therapeutic candidates such as ACI-24.060 (anti-Abeta immunotherapy) and ACI-35.030 (anti-pTau immunotherapy), as well as diagnostic PET tracers for Tau and alpha-synuclein.

Revenue is primarily driven by upfront payments, milestone payments, and royalties from collaboration and license agreements with pharmaceutical partners for the development of its product candidates.